Status: Recruiting
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Participants needed: 100
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Acrivon TherapeuticsUpdated: Mar 23, 2026Locations: 15
Eligibility criteria
Signed written informed consent. [+7]
Participants with known symptomatic brain metastases. [+4]